Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Steuerwald, Nury M ^a   Foureau, David M ^a   Norton, H James ^a   Zhou, Jie ^a   Parsons, Judith C ^a   Chalasani, Naga ^b   Fontana, Robert J ^c   Watkins, Paul B ^d   Lee, William M ^e   Reddy, K Rajender ^f   Stolz, Andrew ^g   Talwalkar, Jayant ^h   Davern, Timothy ⁱ   Saha, Dhanonjoy ^a   Bell, Lauren N ^b   Barnhart, Huiman ^j   Gu, Jiezhun ^j   Serrano, Jose ^k   Bonkovsky, Herbert L ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h MAYO CLINIC   (United States)

ⁱ CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; COHORT STUDIES; CYTOKINES; DRUG-INDUCED LIVER INJURY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY, INNATE; MODELS, IMMUNOLOGICAL; PROGNOSIS;

EID: 84893663493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081974     Document Type: Article

References (50)

1. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ et al. (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137: 947-954. doi:10.7326/0003- 4819-137-12-200212170-00007. PubMed: 12484709.
2. Reuben A, Koch DG, Lee WM (2010) Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52: 2065-2076. doi:10.1002/hep.23937. PubMed: 20949552.
3. Björnsson E (2010) Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 32: 3-13. PubMed: 20374223.
4. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4: 489-499. doi:10.1038/nrd1750. PubMed: 15931258.
5. Shi Q, Hong H, Senior J, Tong W (2010) Biomarkers for drug-induced liver injury. Expert. Rev Gastroenterol Hepatol 4: 225-234. doi:10.1586/egh.10.8.
6. Chalasani N, Björnsson E (2010) Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138: 2246-2259. doi:10.1053/j. gastro.2010.04.001. PubMed: 20394749.
7. Au JS, Navarro VJ, Rossi S (2011) Review article: Drug-induced liver injury - its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther 34: 11-20. doi:10.1111/j.1365-2036.2011.04674.x. PubMed: 21539586.
8. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, et al. (2008) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135: 1924-1934, 1934 e1921-1924
9. Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM et al. (2007) Druginduced liver injury at an Asian center: a prospective study. Liver Int 27: 465-474. doi:10.1111/j.1478-3231.2007.01461.x. PubMed: 17403186.
10. Bonkovsky HL, Shedlofsky SI, Jones DP, Russo M (2012) "Drug-induced liver injury". Chapter 25. In: TD BoyerMP MannsA Sanyal. Zakin and Boyer's Hepatology - a textbook of liver disease, 6th edition, Saunder-Elsevier, Philadelphia. pp. 417-461.
11. Zimmerman HJ (1999) Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver: 2nd edition. Lippincott Williams & Wilkins. 789 pp.
12. Takayama H, Miyake Y, Nouso K, Ikeda F, Shiraha H et al. (2011) Serum levels of platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic factors for patients with fulminant hepatic failure. J Gastroenterol Hepatol 26: 116-121. doi:10.1111/j.1440-1746.2010.06441.x. PubMed: 21175804.
13. Pachkoria K, Lucena MI, Crespo E, Ruiz-Cabello F, Lopez-Ortega S et al. (2008) Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 49: 107-114. doi:10.1016/j.jhep.2008. 03.017. PubMed: 18485518.
14. Laverty HG, Antoine DJ, Benson C, Chaponda M, Williams D et al. (2010) The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol 66: 961-976. doi:10.1007/s00228-010-0862-x. PubMed: 20694460.
15. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB et al. (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39: 1430-1440. doi:10.1002/hep.20205. PubMed: 15122773.
16. Li J, Zhu X, Liu F, Cai P, Sanders C et al. (2010) Cytokine and autoantibody patterns in acute liver failure. J Immunotoxicol 7: 157-164. doi:10.3109/15476910903501748. PubMed: 20039781.
17. Feng D, Wang Y, Xu Y, Luo Q, Lan B et al. (2009) Interleukin 10 deficiency exacerbates halothane induced liver injury by increasing interleukin 8 expression and neutrophil infiltration. Biochem Pharmacol 77: 277-284. doi:10.1016/j.bcp.2008.09.028. PubMed: 18940183.
18. Kobayashi M, Higuchi S, Mizuno K, Tsuneyama K, Fukami T et al. (2010) Interleukin-17 is involved in alpha-naphthylisothiocyanateinduced liver injury in mice. Toxicology 275: 50-57. doi:10.1016/j.tox.2010.05.011. PubMed: 20594950.
19. Higuchi S, Kobayashi M, Yoshikawa Y, Tsuneyama K, Fukami T et al. (2011) IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol Lett 200: 139-145. doi:10.1016/j.toxlet.2010.11.006. PubMed:21094227.
20. Kobayashi E, Kobayashi M, Tsuneyama K, Fukami T, Nakajima M et al. (2009) Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol Sci 111: 302-310. doi:10.1093/toxsci/kfp165. PubMed:19633216.
21. Higuchi S, Kobayashi M, Yano A, Tsuneyama K, Fukami T et al. (2012) Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. J Appl Toxicol, 32: 815-22. PubMed: 21735453.
22. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T et al. (2009) Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 32: 55-68. doi:10.2165/00002018-200932010-00005. PubMed: 19132805.
23. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N et al. (2010) Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51: 2117-2126. doi:10.1002/hep.23577. PubMed: 20512999.
24. Bell LN, Vuppalanchi R, Watkins PB, Bonkovsky HL, Serrano J et al. (2012) Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 35: 600-612. doi:10.1111/j.1365-2036.2011.04982.x. PubMed: 22403816.
25. Steuerwald N, Parsons J, Norton HJ, Saha D, Chalasani LP et al. (2011) Chemokine/cytokine profiles in patients with acute DILI: results from the US Drug-Induced Liver Injury Network. Hepatology 54: Abstract: 359. doi:10.1016/S0168-8278(11)60904-5.
26. Egwuagu CE (2009) STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine 47: 149-156. doi:10.1016/j.cyto.2009.07.003. PubMed: 19648026.
27. Jutel M, Akdis CA (2011) T-cell subset regulation in atopy. Curr Allergy Asthma Rep 11: 139-145. doi:10.1007/s11882-011-0178-7. PubMed: 21271314.
28. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M et al. (2005) Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307: 734-738. doi:10.1126/science.1103685. PubMed: 15692052.
29. Mandal P, Pritchard MT, Nagy LE (2010) Anti-inflammatory pathways and alcoholic liver disease: role of an adiponectin/interleukin-10/heme oxygenase-1 pathway. World J Gastroenterol 16: 1330-1336. doi:10.3748/wjg.v16.i11.1330. PubMed: 20238399.
30. Mumm JB, Oft M (2011) Subversion and coercion: the art of redirecting tumor immune surveillance. Curr Top Microbiol Immunol 344: 25-39. PubMed: 20490777.
31. Wiesner R, Edwards E, Freeman R, Harper A, Kim R et al. (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124: 91-96. doi:10.1053/gast.2003.50016. PubMed: 12512033.
32. Callan HE, Jenkins RE, Maggs JL, Lavergne SN, Clarke SE et al. (2009) Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol 22: 937-948. doi:10.1021/tx900034r. PubMed: 19358516.
33. Meng X, Jenkins RE, Berry NG, Maggs JL, Farrell J et al. (2011) Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. J Pharmacol Exp Ther 338: 841-849. doi:10.1124/jpet.111.183871. PubMed: 21680886.
34. Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J et al. (2013) Human leukocyte antigen (HLA)-B*57:01-restricted activation of drugspecific T cells provides the immunological basis for flucloxacillininduced liver injury. Hepatology 57: 727-739. doi:10.1002/hep.26077. PubMed: 22987284.
35. Bonkowsky HL, Brisbane J (1976) Colitis and hepatitis caused by methyldopa. JAMA 236: 1602-1603. doi:10.1001/jama. 1976.03270150036028. PubMed: 989134.
36. Tujios S, Fontana RJ (2011) Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 8: 202-211. doi: 10.1038/nrgastro.2011.22. PubMed: 21386809.
37. Uetrecht J (2009) Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 29: 383-392. doi:10.1055/s-0029-1240007. PubMed: 19826972.
38. Nakashima H, Akahoshi M, Masutani K (2006) Th1/Th2 balance of SLE patients with lupus nephritis. Rinsho Byori 54: 706-713. PubMed: 16913661.
39. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C et al. (2011) The DRESS syndrome: a literature review. Am J Med 124: 588-597. doi:10.1016/j. amjmed.2011.01.017. PubMed: 21592453.
40. Chalasani N, Vuppalanchi R, Navarro VJ, Fontana RJ, Bonkovsky HL et al. (2012) Acute liver injury due to flavocoxid (Limbrel®), a medical food for osteoarthritis: a case series. Ann Intern Med (In press).
41. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, et al. (2011) Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 9: 517-523 e513
42. Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H et al. (2010) Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 32: 1174-1183. doi:10.1111/j.1365-2036. 2010.04449.x. PubMed: 20815829.
43. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH et al. (2013) Liver Injury from Tumor Necrosis Factor-alpha Antagonists: Analysis of 34 Cases. Clin Gastroenterol Hepatol.
44. Blendis L, Dotan I (2004) Anti-TNF therapy for severe acute alcoholic hepatitis: what went wrong? Gastroenterology 127: 1637-1639. doi:10.1053/j.gastro.2004.09.089. PubMed: 15521033.
45. Hill DB, McClain CJ (2004) Anti-TNF therapy in alcoholic hepatitis. Am J Gastroenterol 99: 261-263. doi:10.1111/j.1572-0241.2004.04033.x. PubMed: 15046214.
46. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA et al. (2003) Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38: 419-425. doi:10.1016/S0168-8278(02)00442-7. PubMed: 12663232.
47. Poynard T, Thabut D, Chryssostalis A, Taieb J, Ratziu V (2003) Antitumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol 38: 518-520. doi:10.1016/S0270- 9139(03)80785-1. PubMed: 12663246.
48. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H et al. (2003) Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38: 859-868. doi:10.1002/hep. 1840380412. PubMed: 14512873.
49. Levy O, Zhao W, Mortensen LJ, Leblanc S, Tsang K et al. (2013) mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood, 122: e23-32. PubMed: 23980067.
50. Hirayama S, Sato M, Loisel-Meyer S, Matsuda Y, Oishi H et al. (2013) Lentivirus IL-10 gene therapy down-regulates IL-17 and attenuates mouse orthotopic lung allograft rejection. Am J Transplant 13: 1586-1593. doi:10.1111/ajt.12230. PubMed: 23601206.